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Recent studies have demonstrated that transforming growth factor beta (TGF-β1)-induced antiapoptotic factor (TIAF1)
is able to form aggregates in the hippocampi of middle-aged normal individuals. The aggregating TIAF1 induces
generation of amyloid beta (Aβ) for causing neurodegeneration. Intriguingly, TIAF1 aggregates are shown, together
with Smad4 and Aβ, in the cancer stroma and peritumor capsules of many solid tumors. During lung cancer
progression, for example, TIAF1 and amyloid fibrils are significantly upregulated in the cancer stroma. Aggregates of
TIAF1 and Aβ are shown on the interface between metastatic lung cancer cells and the brain tissues. Conceivably,
these peritumor materials are needed for cancer cells to survive. In vitro experiments revealed that TIAF1 is a crucial
component for tumor suppressors p53 and WWOX-mediated tumor suppression and apoptosis. While metastatic lung
cancer cells are frequently devoid of WWOX and p53, we provide new perspectives regarding the role of TIAF1 in the
pathogenesis of lung cancer development, and propose a therapeutic approach for targeting TIAF1.
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Tumor suppressors p53 and WWOX have been shown to
play critical roles in apoptosis and control of cancer progres-
sion [1-3]. WW domain-containing oxidoreductase, desig-
nated as WWOX, FOR, or WOX1, is encoded by human
or mouse WWOX/Wwox gene. The full-length WWOX
protein is composed of two N-terminal WW domains and a
C-terminal short-chain alcohol dehydrogenase/reductase
(SDR) domain (Figure 1) [3]. WWOX may act as an alterna-
tive receptor for sex steroid hormones, since its SDR
domain possesses a hormone-binding NSYK motif [4,5].
The first WW domain interacts with proteins possessing
a PPxY-motif(s), including AP-2, p73, ErbB4, Ezrin, SIM-
PLE, c-Jun, RUNX2 and many others [3]. Transiently
overexpressed WWOX prevents the relocation of transcrip-
tion factors AP-2, p73, ErbB4, c-Jun and RUNX2 to accu-
mulate in the nuclei in vitro. However, the observations
in vitro do not appear to be true in vivo. Activated Wwox
with Tyr33 phosphorylation, along with transcription fac-
tors c-Jun, CREB, JNK1, ATF3 and NF-κB, rapidly* Correspondence: nschang13827@gmail.com
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in any medium, provided the original work is pundergoes relocation to the nuclei in axotomized neurons
in sciatic nerve transection in rats [6]. When WWOX
undergoes activation via phosphorylation at Tyr33 (prob-
ably by SRC kinase), it binds a broad spectrum of proteins
without the PPxY motif [3,5].
The domain structure of p53 includes a natively unfolded
N-terminal transactivation domains TAD1 and TAD2, a
proline-rich region (PRR), a central DNA-binding domain,
and a C-terminal tetramerization domain [2,7]. Activated
p53 causes cell cycle arrest, initiates DNA repair, and may
lead to apoptosis [7]. p53 transactivates cyclin-dependent
kinase inhibitor p21 or microRNA miR34 to induce cell
cycle arrest [7]. For apoptosis, p53 transactivates
proapoptotic genes such as BAX, PUMA, SCOTIN, and
FAS, and inhibits the antiapoptotic gene BCL2 [7]. Under
stress conditions (e.g. UV irradiation and chemotherapeu-
tic drugs), activated WWOX physically binds Ser46-
phosphorylated p53. This binding allows WWOX to
stabilize p53, and both proteins act together in causing
apoptosis [3,5] (Figure 1).Role of p53 and WWOX in blocking cancer
initiation and progression
Cancer initiation and progression is generally considered as
a consequence of gene mutation or epigenetic inactivation
of tumor suppressors. It is believed that mutations in 2Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 1 WWOX signaling. The full-length WWOX or WOX1 has two N-terminal WW domains and a C-terminal short-chain alcohol
dehydrogenase/reductase (ADH/SDR) domain [1-5]. A nuclear localization signal (NLS) is located between the WW domains. Sex steroid
hormones may interact with the NSYK motif in the ADH/SDR domain [4,5]. Under stress stimuli, tyrosine kinase SRC and probably other kinases
induce WWOX activation via Tyr33 phosphorylation. Activated WWOX binds Ser46-phosphorylated p53, and relocates to the mitochondria and
nuclei to induce apoptosis. JNK1 and Zfra bind WWOX and counteract its-mediated apoptosis. The first WW domain of WWOX interacts with
PPxY motif-containing transcription factors, including AP-2γ, p73, ERBB4, c-Jun and RUNX2. The binding allows transiently overexpressed WWOX
to prevent relocation of transcription factors to the nucleus in vitro. However, the event does not work in vivo [6]. Phosphorylated Ezrin binds and
anchors WWOX to the membrane/cytoskeleton area. Activated tyrosine kinase ACK1 phosphorylates WWOX at Tyr287 for polyubiquitination and
proteosomal degradation.
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hypothesis” [8]. Recent development revealed that even
partial inactivation of tumor suppressors critically contrib-
utes to tumorigenesis [8]. Despite these, it is not surprising
to find that many tumor suppressor proteins, e.g. p53,
WWOX, Smad4, and others, are significantly upregulated
during the early stage of cancer progression [3,9,10]. Func-
tional significance of these proteins in blocking cancer pro-
gression at the early stage is largely unknown. However, a
good possibility is that these proteins are functionally
inactivated.
Proapoptotic p53, for example, is functionally inactivated
by fortilin, an anti-apoptotic protein [11,12]. Fortilin phys-
ically interacts with the sequence-specific DNA binding
domain of p53. Oncogenic monocarboxylic acid trans-
porter 1 (MCT-1) abolishes the p53 function by enhancing
its degradation via the ubiquitin/proteasome system [13].
Under stress conditions, NF-κB acts as an oncoproteinto promote cell division and survival and block the
proapoptotic function of p53 [14]. Mdm2 and Mdmx
abolish the stability of p53 [15]. Mdm2 is an E3 ubiquitin
ligase that causes p53 ubiquitination and proteasomal deg-
radation. In contrast, Mdmx does not induce p53 degrad-
ation, but inhibits p53 by masking its transcriptional
activation domain. When WWOX undergoes Tyr33 phos-
phorylation, the activated protein binds and stabilizes
Ser46-phosphorylated p53 [3,16]. cJun N-terminal kinase
(JNK1) binds and functionally counteracts with WWOX
in apoptosis [17-20]. When JNK1 is blocked by chemical
inhibitors (e.g. SP600125), WWOX-mediated apoptosis is
enhanced. Zfra (zinc finger-like protein that regulates
apoptosis) participates in the mitochondrial apoptosis and
binds WWOX to its N-terminal first WW domain and
C-terminal SDR domain, which results in functional
antagonism in causing apoptosis [21,22]. Together,
functional antagonism is well known among proapoptotic
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a direct functional antagonism between defined tumor
suppressors.Silencing WWOX gene promoter by
hypermethylation
Promoter hypermethylation is believed to block protein
expression, and epigenetic control can touch over a large
region of chromosomes in a coordinated manner [23,24].
Promoters for tumor suppressor genes WWOX and Fhit
are frequently hypermethylated and silenced in metastatic
cancers [25,26]. Alternatively, tumor suppressors are
inactivated due to gene mutation, fragmentation, or
interchromosomal recombination at the later cancer pro-
gression and metastasis stages. Nonetheless, expression of
tumor suppressor WWOX is increased during the early
stages of cancer initiation and growth, and is then dramat-
ically reduced at the late stages of differentiation in skin
cancer both in humans and mice [3,10]. Translational
blockade is shown to be involved in the downregulation of
WWOX/Wwox protein in humans and mice [10].Lack of WWOX and increased migration in
metastatic cancers
In most cases, metastatic cancer cells do not have func-
tional tumor suppressors such as WWOX and p53
[3,4,25,26]. How tumor suppressors affect normal cell
migration and cancer cell metastasis is largely unknown.
Ectopic WWOX affects ovarian cell attachment and mi-
gration on fibronectin-enriched extracellular matrix,
and, conversely, loss of WWOX facilitates ovarian cell
migration [27]. While epithelial-mesenchymal transition
is an essential step toward cancer cell metastasis, it ap-
pears that many signal pathways converge on several
transcription factors, including zinc finger proteins Snail
and Slug, Twist, ZEB 1/2, and Smads, and the event re-
sults in the morphological transition and metastasis [28].
Cancer cell metastasis is affected by the surrounding
tumor microenvironments. Metastatic lung cancer cells
appear to be able to detect alterations in the environ-
mental cues, so that they successfully migrate to target
organs and settle properly [29,30]. Non-small-cell lung
carcinomas (NSCLC) frequently migrate to the contra-
lateral lung, the brain and to organs such as adrenal
glands, liver and bones [29]. Whether lung cancer cells
specifically select susceptible sites in the endothelial lin-
ing of blood vessels for docking and penetration into or-
gans is largely unknown.
Many types of metastatic cancers utilize the CXCR4/
CXCL12 signaling axis to reach the targets [31-33]. High
levels of functional CXCR4 receptors are expressed in
small-cell lung cancer (SCLC) cells. Binding of chemo-
kine stromal derived factor-1 (SDF-1/CXCL12) to theCXCR4 receptors increases the expression of integrin-
mediated adhesion in SCLC to target cells.
TIAF1-p53-WWOX is an axis of tumor suppression
TIAF1 is a transforming growth beta (TGF-β)-induced
12-kDa protein [34-38]. This protein was originally
shown to participate in the regulation of the tumor ne-
crosis factor (TNF) pathway. TIAF1 also controls the
signaling of TNF receptor adaptor proteins such as
TRADD (TNFR1-associated death domain protein),
FADD (FAS-associated death domain-containing pro-
tein), and RIP (receptor-interacting serine-threonine kin-
ase) [38]. As a TGF-β-induced protein, TIAF1 acts
similarly to that of TGF-β1 [37,38]. For example, TGF-
β1 and transiently overexpressed TIAF1 support the
growth of fibroblasts [37]. However, epithelial and mono-
cytic cells, as well as many non-fibroblasts, are sensitive to
the growth suppression and apoptosis by TGF-β1 and
transiently overexpressed TIAF1. In monocytic U937 cells,
for example, ectopic TIAF1 increases the expression of p53
and Cip1/p21 and suppresses ERK phosphorylation, which
leads to cell growth inhibition and apoptosis [36,37].
TIAF1 is essential for cell death caused by tumor sup-
pressors p53 and WWOX and dominant-negative JNK1
[36]. When TIAF1 expression is knocked down by small
interfering RNA (siRNA), UV irradiation-mediated p53
activation, via Ser15 phosphorylation and nuclear accu-
mulation, is blocked [36]. Importantly, transiently
overexpressed TIAF1, p53 and WWOX work synergis-
tically in suppressing anchorage-independent growth,
blocking cell migration, and causing apoptosis in vitro
[34]. When one of the components is missing, the apop-
totic function of the TIAF1-p53-WWOX trio is signifi-
cantly reduced, suggesting that the complex is an axis of
tumor suppression [34].
p53, WWOX and TIAF1 in the TGF-β signaling and
SMAD-responsive promoter activation
p53, WWOX and TIAF1 participate in the pathway of
TGF-β/Smad signaling. In the canonical signaling, mem-
brane type II TGF-β receptor (TβRII) is responsible for
binding extracellular TGF-β1, β2 or β3, followed by
recruiting TβRI and subsequent activation and complex
formation of Smad2, 3 and 4. TβRII is a constitutively ac-
tive serine/threonine kinase. Upon stimulation with TGF-β,
TβRII phosphorylates and binds the serine/threonine kin-
ase TβRI. Then, the receptor complex, containing two
TβRII and two TβRI, phosphorylates Smad2 and 3 for sub-
sequent recruiting Smad4. The Smad2/3/4 complex trans-
locates to the nucleus to mediate gene transcription [39]
(Figure 2). Mutant p53 binds TβRII promoter to block the
expression of TβRII [40]. However, wild type p53 and Smad
proteins interact with AFP and Mix2 promoters for either
enhancing or suppressing the promoter activity [40]. We
Figure 2 TGF-β1-initiated signal pathways that converge to WWOX, TIAF1, p53, Hyal-2, and Smad4. TGF-β1 initiates several signal
pathways: i) In the canonical signaling, extracellular TGF-β1 binds TβRII, followed by recruiting TβRI for subsequent activation and complex
formation of Smad2, 3 and 4. The Smad2/3/4 complex mediates gene transcription in the nucleus [39]. ii) Alternatively, TGF-β1 utilizes membrane
hyaluronidase Hyal-2 as a receptor for signaling the complex formation of Hyal-2 with WWOX and Smad4 to control SMAD-responsive promoter
activation [41]. iii) Additionally, TGF-β1 induces the complex formation of TIAF1 with Smad4 to regulate the SMAD-responsive promoter
activation [35]. iv) WWOX binds and prevents p53 degradation and both proteins exert apoptosis synergistically [2,3]. p53-WWOX-TIAF1 is an axis
of tumor suppression [34,36]. TGF-β1 is likely to converge the TGF-β1-initiated signal pathways to the complex formation of WWOX, TIAF1, p53,
Hyal-2, and Smad4. TIAF1 undergoes aggregation during aberrant TGF-β signaling [35]. WWOX: blue; Hyal-2: light blue; TIAF1: pink; p53: light
green; Smad4: orange. Red circle: phosphorylation.
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Hyal-2, and the binding leads to complex formation of
Hyal-2 with WWOX and Smad4 for regulating the SMAD-
responsive promoter activation [41] (Figure 2). Excessive
SMAD-regulated promoter activation induces cell death
[41]. Most recently, we determined that TGF-β1 signals the
binding of TIAF1 with Smad4, and the complex relocates
to the nucleus to modulate gene transcription governed by
Smad4 [35]. Overall, TGF-β1-initiated signal pathways are
likely to converge to the complex formation of WWOX,
Hyal-2, TIAF1, p53, and Smad4 for regulating the promoter
activation governed by SMAD (Figure 2).
TIAF1 binds Smad4 of the TGF-β/Smad signaling, and
that transiently overexpressed TIAF1 blocks SMAD-
dependent promoter activation [34]. When TIAF1 is
knocked down by siRNA, spontaneous activation of
Smad proteins occurs as their accumulation in the nu-
cleus [34]. In parallel, when TIAF1 level is low, spontan-
eous activation of the promoter governed by the SMAD
complex occurs [34]. Most intriguingly, in the absence
of endogenous p53, TIAF1 undergoes self-aggregation
and simultaneously activates the SMAD-regulated pro-
moter [35]. In parallel with the protein expression of
WWOX [10], TIAF1 is upregulated in developing tu-
mors, but may disappear in established metastatic cancer
cells [34]. As an axis of tumor suppression, the absenceof WWOX-p53-TIAF1 trio favors the growth of meta-
static cancer cells.
TIAF1 does not directly interact with p53 [34,36].
However, TIAF1 is needed for UV irradiation-induced
p53 activation (with Ser15 phosphorylation) and nuclear
accumulation [36]. Without TIAF1, no p53 activation
occurs. WWOX physically binds p53 and stabilizes its
function [10]. Data from both yeast two-hybrid and För-
ster resonance energy transfer (FRET) analyses revealed
that WWOX acts as a bridge for the indirect interaction
between p53 and TIAF1 (Chang et al., unpublished).
TGF-β1 induces the differentiation of regulatory T
cells (Treg), and that TIAF1 expression is significantly
increased during cell differentiation [42]. TIAF1 is con-
sidered as one of the Treg signature proteins [42]. TIAF1
is also involved in allograft rejection, as its level is sig-
nificantly increased in activated Th2 helper T lympho-
cytes in patients with chronic kidney and liver allograft
rejection [43]. In addition, TIAF1 is associated with
Hirschsprung's disease, a congenital complex disorder of
intestinal innervation [44].
TGF-β, microenvironment and cell-cell contacts
affect TIAF1 aggregation
In response to TGF-β1 or -β2, TIAF1 undergoes self-
aggregation in the cultured cells [34]. The event can
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TβRII/RI/Smads [34]. TIAF1 aggregation occurs prob-
ably as a result of an aberrant TGF-β signaling in cancer
cells, as well as in the hippocampus [34,35]. Also, when
cells are exposed to environmental stress, TIAF1 under-
goes self-aggregation, which exhibits as a ladder-like
protein polymerization pattern in SDS-PAGE [34]. The
overly aggregated TIAF1 induces degradation of amyloid
precursor protein (APP), super-induction of Aβ, and ul-
timately cell death in vitro [34]. Caspase inhibitors block
the cell death, suggesting that caspases participate in the
TIAF1-induced apoptosis.
Microenvironment and cell-cell contacts affect the TGF-
β1 induction of endogenous TIAF1 expression and self-
aggregation. Also, TGF-β regulates cancer cell and stroma
interactions, and that controls the progression of cancer
growth [45]. When lung cancer cells are grown on an extra-
cellular matrix (ECM) derived from another cell type, the
lung cells have apparently received the environmental stress
that leads to the generation of endogenous TIAF1 and Aβ
aggregates [34]. No ubiquitination is involved in the TIAF1Figure 3 Expression of TIAF1 and amyloid fibrils in U87-MG glioma ce
of nude mice. Two months later, the mice were sacrificed. Shown is the U8
increased expression of TIAF1 and amyloid fibrils, compared to normal mic
homemade TIAF1 antibody and commercial amyloid fibril antibody were upolymerization. Intriguingly, the polymerizing TIAF1 in-
creases the expression of tumor suppressors Smad4 and
WWOX [34]. And, WWOX in turn upregulates the TIAF1
expression [34]. Smad4 remains a monomer, whereas
WWOX may become polymerized as well. Dominant nega-
tive TIAF1 is able to block WWOX expression [34].
Furthermore, when fibroblasts and neuroblastoma cells
were co-cultured on the ECM of prostate DU145 cells for at
least 48 hr, endogenous TIAF1 expression and aggregation
were demonstrated in both cells [34]. No TIAF1 aggregate
formation was observed by culturing fibroblasts or neuro-
blastomas alone on the ECM [34]. Additionally, TIAF1 ag-
gregates are present on the interface between metastatic lung
cancer cells and the brain cells in vivo [34]. Thus, when two
distinct types of cells encounter each other in an unfavorable
microenvironment, endogenous TIAF1 aggregation occurs.
TIAF1 aggregation occurs in tumor progression
and metastasis in vivo
TIAF1 participates in the initiation of Alzheimer’s disease
[35]. We have determined that hippocampal TIAF1lls in the lung. U87-MG glioma cells were inoculated in both flanks
7-MG cell metastatic to the lung. Each solid tumor lesion has
e (data not shown). Both proteins appear to localize intracellularly. A
sed, as described [34,35].
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prior to the generation of Aβ plaques in Alzheimer’s disease
at 75–90 years old [35]. In parallel with this finding, in vitro
analysis showed that aggregating TIAF1 causes APP deg-
radation and generation of Aβ [35]. Whether aggregating
TIAF1 induces caspase activation for leading to APP deg-
radation is unknown. Upregulation of TIAF1 is also shown
during cancer progression and metastasis [34]. When meta-
static U87-MG glioma cells, for instance, were subcutane-
ously inoculated in both flanks of nude mice, the cells were
metastatic to the lung. Expression of TIAF1 and amyloid fi-
brils is shown in the growing solid tumor (Figure 3).Figure 4 TIAF1 is a potential target for lung cancer therapy. A.
When cancer cells are transiently overexpressed with TIAF1, a
portion of the expressed TIAF1 localizes on the cell membrane/
cytoskeleton area or intercellular junctions (marked in red) [37],
which probably assists cells to stick to each other that leads to solid
tumor formation. TIAF1 is associated with stem cell pluripotency
[46]. It is reasonable to postulate that when a lung cancer stem cell
starts to grow, it probably needs the expression of TIAF1 to allow
cells to stick to each other in order to proliferate. B. Therefore,
blocking TIAF1 expression by appropriate chemicals, siRNA, or
dominant negatives could result in suppression of lung cancer stem
cell proliferation.TIAF1 aggregates in the metastatic lung cancer
cells in the brain
It appears that cancer cells could tolerate more microenvi-
ronmental stress than normal cells, as cancer cells tend
to utilize local or autocrine TGF-β in building up their
own niche. Conceivably, upon reaching and selectively
attaching to the docking site in the brain, a single meta-
static lung cancer cell must face the challenge of survival.
The cell needs to divide and proliferate quickly, and build
itself own niche by utilizing available sources from the
brain tissue or its own TGF-β. The concern is whether the
brain tissue recognizes the cancer cell as foreign. The local
glial cells or immune cells may come to attack the invad-
ing cancer cell. A successfully built solid tumor normally
possesses a peritumor capsule. For example, when meta-
static small-cell lung cancer cells migrate to the brain,
TIAF1 and Aβ aggregates are shown on the border be-
tween cancer and brain cells. Or, the protein aggregates
are present in the tumor mass [34].
During solid lung tumor formation in the brain, ECM
proteins continue to accumulate and they can organize or-
derly in the matrix or become aggregated in an irregular
manner [34]. The ECM aggregates are located inside the
tumor mass, or may be present on the borderline between
brain cells and the metastatic lung cancer [34]. Quite fre-
quently, TIAFI and Aβ are present in these protein aggre-
gates. Self-aggregation of TIAF1 has been shown to
induce phosphorylation of APP, followed by generation of
Aβ and amyloid fibrils [35]. The resulting Aβ fails to cause
cancer cell death, whereas it is likely to make damage to
neurons or initiation of neurodegeneration. Indeed, no
apoptotic lung cancer cells have been shown within the
peritumor protein aggregates [34], suggesting that these
protein aggregates act as a “protective shield” for the pro-
gression of lung cancer cells in the brain.
Intriguingly, when metastatic cancer cells have well
established their niche, intracellular TIAF1 disappears
significantly in the tumor masses [34]. However, TIAF1,
Smad4, Aβ, and many other proteins are components of
the fibrous aggregates in the peritumor capsules. Theextracellular aggregated TIAF1 and Smad4 are probably
functionally inactive.Concluding remarks
TGF-β1 induces TIAF1 self-aggregation, and the aggre-
gating proteins bind Smad4 and cause Aβ generation.
These protein aggregates are likely to induce apoptosis
via activation of caspases, as caspase inhibitors can block
the cell death [35]. However, cancer cells appear to suc-
cessfully survive from the stress. The TIAF1-Smad4-Aβ
protein aggregates are frequently seen in the peritumor
capsules, which are crucial for solid tumor growth and
protection. However, the relative concentrations of
TIAF1 and Smad4 must be balanced. If cells have a
greater amount of TIAF1 than Smad4, they survive upon
challenge with TGF-β1. However, when cells express a
greater amount of Smad4 than TIAF1, they are highly
sensitive to TGF-β1-induced apoptosis [35].
During cancer progression, the expression profiles for
WWOX and TIAF1 appear similarly. Both proteins are
significantly upregulated during the early phases of be-
nign tumor formation. When tumors acquire their meta-
static potential, both proteins are dramatically reduced.
WWOX induces the expression of TIAF1, and enhances
the transcriptional activation of promoters governed by
SMAD and NF-κB [34,35]. TIAF1 in turn induces the
expression of Smad4 and Aβ, depending upon the status
of TIAF1 self-aggregation. Intriguingly, under p53-free
environment, TIAF1 starts to undergo self-aggregation
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governed promoter [35].
TIAF1 gene participates in human embryonic stem cell
self-renewal and pluripotency [46], and is also involved in
melanogenesis [47] and genome stability [48]. Given its
potential role in cancer progression, TIAF1 can be an ideal
target for therapeutic drugs. Transiently overexpressed
TIAF1 induces aggregation of monocytic cells and other
cancer cells in vitro [37] (Figure 4). It appears that the
overexpressed cell surface TIAF1 serves as a molecular
glue, plus integrins and matrix proteins, to allow cancer
cells to adhere to each other. Thus, it is reasonable to pos-
tulate that blocking TIAF1 expression by appropriate
chemicals, siRNA, or dominant negative TIAF1 could re-
sult in suppression of lung cancer stem cell growth and
progression.
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